A retrospective study has shown that a high systemic immune-inflammation index (SII) score is an independent indicator for poor overall survival in patients with metastatic renal cell carcinoma (mRCC) treated with tyrosine kinase inhibitors (TKIs). The researchers suggest that the neutrophil and platelet counts in the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) model to predict patient risk could be replaced with the SII score to improve accuracy.

Read more in Practice Update here